Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression

RAS is the most frequently mutated oncogene in human cancers. Despite decades of effort, anti-RAS therapies have remained elusive. Isoprenylcysteine carboxylmethyltransferase (ICMT) methylates RAS and other CaaX-containing proteins, but its potential as a target for cancer therapy has not been fully...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Court, Helen, Amoyel, Marc, Hackman, Michael, Lee, Kyoung Eun, Xu, Ruliang, Miller, George, Bar-Sagi, Dafna, Bach, Erika A., Bergö, Martin O., Philips, Mark R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3809775/
https://ncbi.nlm.nih.gov/pubmed/24216479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI65764
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller